menu
    • menu
    [{"orgOrder":0,"company":"OrthoCellix","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Merger","leadProduct":"Autologous Cartilagenous Tissue","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"OrthoCellix","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"OrthoCellix \/ Carisma Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"OrthoCellix \/ Carisma Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by OrthoCellix

    Menu

    OrthoCellix

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OrthoCellix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            OrthoCellix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NeoCart,Autologous Cartilagenous Tissue

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase III

                            Sponsor : Carisma Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement

                            Details : The combined company will focus on the development of OrthoCellix’s NeoCart technology for the treatment of knee articular cartilage defects and plans to initiate a Phase 3 trial for NeoCart.

                            Product Name : NeoCart

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            June 23, 2025

                            Lead Product(s) : NeoCart,Autologous Cartilagenous Tissue

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase III

                            Sponsor : Carisma Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth